CAS 1234480-46-6

6H-Pyrimido[4,5-b][1,4]benzodiazepin-6-one, 5,11-dihydro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-11-methyl-

CAS : 1234480-46-6

Formule : C₂₄H₂₇N₇O₂

Degré de pureté : 97%

Couleur et forme : Solid

Masse moléculaire : 445.5169

Ref: IN-DA000KKY

XMD8-87

CAS : 1234480-46-6

XMD8-87

Degré de pureté : ≥95%

Masse moléculaire : 445.52g/mol

Ref: 54-BUP09924

XMD8-87

CAS : 1234480-46-6

XMD8-87 (ACK1-B19), a TNK2 inhibitor, strongly blocks TNK2 phosphorylation and mutations in tumors.

Formule : C₂₄H₂₇N₇O₂

Degré de pureté : 98.05% - 99.89%

Couleur et forme : Solid

Masse moléculaire : 445.52

Ref: TM-T3709

XMD8-87

CAS : 1234480-46-6

XMD8-87 is a cancer drug under development by Novartis that inhibits the growth of tumor cells by blocking the activity of kinases. XMD8-87 is selective for SRC family kinases and has been shown to inhibit the growth of tumor cells in vitro and in vivo. The drug has also been shown to have an effect on other types of cancer cells, including lung, colon, prostate, and breast cancers. XMD8-87 binds to a region targeted by many drugs that are currently used for cancer treatment, including dasatinib and imatinib. This may make it possible to use XMD8-87 as a substitute or complementary treatment option.

Formule : C₂₄H₂₇N₇O₂

Degré de pureté : Min. 95%

Masse moléculaire : 445.52 g/mol

Ref: 3D-JZB48046